Cargando…
Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identified pati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316736/ https://www.ncbi.nlm.nih.gov/pubmed/32587320 http://dx.doi.org/10.1038/s41598-020-67504-6 |
_version_ | 1783550483910098944 |
---|---|
author | Thebault, Simon Abdoli, Mohammad Fereshtehnejad, Seyed-Mohammad Tessier, Daniel Tabard-Cossa, Vincent Freedman, Mark S. |
author_facet | Thebault, Simon Abdoli, Mohammad Fereshtehnejad, Seyed-Mohammad Tessier, Daniel Tabard-Cossa, Vincent Freedman, Mark S. |
author_sort | Thebault, Simon |
collection | PubMed |
description | Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identified patients with serum collected within 5 years of first MS symptom onset (baseline) with more than 15 years of routine clinical follow-up. Levels of serum NfL were quantified in patients and matched controls using digital immunoassay (SiMoA HD-1 Analyzer, Quanterix). Sixty-seven patients had a median follow-up of 18.9 years (range 15.0–27.0). The median serum NfL level in patient baseline samples was 10.1 pg/mL, 38.5% higher than median levels in 37 controls (7.26 pg/mL, p = 0.004). Baseline NfL level was most helpful as a sensitive predictive marker to rule out progression; patients with levels less 7.62 pg/mL were 4.3 times less likely to develop an EDSS score of ≥ 4 (p = 0.001) and 7.1 times less likely to develop progressive MS (p = 0.054). Patients with the highest NfL levels (3rd-tertile, > 13.2 pg/mL) progressed most rapidly with an EDSS annual rate of 0.16 (p = 0.004), remaining significant after adjustment for sex, age, and disease-modifying treatment (p = 0.022). This study demonstrates that baseline sNfL is associated with long term clinical disease progression. sNfL may be a sensitive marker of subsequent poor clinical outcomes. |
format | Online Article Text |
id | pubmed-7316736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73167362020-06-26 Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis Thebault, Simon Abdoli, Mohammad Fereshtehnejad, Seyed-Mohammad Tessier, Daniel Tabard-Cossa, Vincent Freedman, Mark S. Sci Rep Article Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identified patients with serum collected within 5 years of first MS symptom onset (baseline) with more than 15 years of routine clinical follow-up. Levels of serum NfL were quantified in patients and matched controls using digital immunoassay (SiMoA HD-1 Analyzer, Quanterix). Sixty-seven patients had a median follow-up of 18.9 years (range 15.0–27.0). The median serum NfL level in patient baseline samples was 10.1 pg/mL, 38.5% higher than median levels in 37 controls (7.26 pg/mL, p = 0.004). Baseline NfL level was most helpful as a sensitive predictive marker to rule out progression; patients with levels less 7.62 pg/mL were 4.3 times less likely to develop an EDSS score of ≥ 4 (p = 0.001) and 7.1 times less likely to develop progressive MS (p = 0.054). Patients with the highest NfL levels (3rd-tertile, > 13.2 pg/mL) progressed most rapidly with an EDSS annual rate of 0.16 (p = 0.004), remaining significant after adjustment for sex, age, and disease-modifying treatment (p = 0.022). This study demonstrates that baseline sNfL is associated with long term clinical disease progression. sNfL may be a sensitive marker of subsequent poor clinical outcomes. Nature Publishing Group UK 2020-06-25 /pmc/articles/PMC7316736/ /pubmed/32587320 http://dx.doi.org/10.1038/s41598-020-67504-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Thebault, Simon Abdoli, Mohammad Fereshtehnejad, Seyed-Mohammad Tessier, Daniel Tabard-Cossa, Vincent Freedman, Mark S. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title_full | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title_fullStr | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title_full_unstemmed | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title_short | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
title_sort | serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316736/ https://www.ncbi.nlm.nih.gov/pubmed/32587320 http://dx.doi.org/10.1038/s41598-020-67504-6 |
work_keys_str_mv | AT thebaultsimon serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT abdolimohammad serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT fereshtehnejadseyedmohammad serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT tessierdaniel serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT tabardcossavincent serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis AT freedmanmarks serumneurofilamentlightchainpredictslongtermclinicaloutcomesinmultiplesclerosis |